Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 87.00 | |
5 mg | In stock | $ 210.00 | |
10 mg | In stock | $ 310.00 | |
25 mg | In stock | $ 586.00 | |
50 mg | In stock | $ 810.00 | |
100 mg | In stock | $ 1,120.00 | |
500 mg | In stock | $ 2,250.00 |
Description | Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity. |
In vivo | Mitoquidone (MTQ) demonstrated good activity in a range of experimental solid tumour models, but was weakly active against standard prescreens such as the P388 murine leukaemia. Twenty-seven patients were treated with MTQ given as a 4-h infusion either once every 21 days (150-600 mg/m2), once a week (200 mg/m2 per week), or as 5 daily doses repeated every 28 days (60-180 mg/m2 per day). Temporary remission of B-symptoms occurred in two patients with lymphoma. Linear pharmacokinetics were observed with a terminal plasma half-life of 2.9 +/- 2.1 h (n = 18 doses). The volume of distribution was 3.4 +/- 2.6 l/kg and plasma clearance was 629 +/- 469 ml/min per m2.[1] |
Molecular Weight | 299.32 |
Formula | C20H13NO2 |
CAS No. | 91753-07-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mitoquidone 91753-07-0 Others inhibitor inhibit